The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
Open accessAbstract
Background: We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker. Methods: We collected individual patient data from 21 studies in which CTC detection by CellSearch was performed in early breast cancer patients treated with NCT. The primary end point was overall survival, analyzed according to CTC detection, using Cox regression models stratified by study. Secondary end points included distant disease-free survival, locoregional relapse-free interval, and pathological complete response. All statistical tests were two-sided. Results: Data from patients were collected before NCT (n = 1574) and before surgery (n = 1200). CTC detection revealed one or more CTCs in 25.2% of patients before NCT; this was associated with tumor size (P < .001). The number of CTCs detected had a detrimental and decremental impact on overall survival (P < .001), distant disease-free survival (P < .001), and locoregional relapse-free interval (P < .001), but not on pathological complete response. Patients with one, two, three to four, and five or more CTCs before NCT displayed hazard ratios of death of 1.09 (95% confidence interval [CI] = 0.65 to 1.69), 2.63 (95% CI = 1.42 to 4.54), 3.83 (95% CI = 2.08 to 6.66), and 6.25 (95% CI = 4.34 to 9.09), respectively. In 861 patients with full data available, adding CTC detection before NCT increased the prognostic ability of multivariable prognostic models for overall survival (P < .001), distant disease-free survival (P < .001), and locoregional relapse-free interval (P = .008). Conclusions: CTC count is an independent and quantitative prognostic factor in early breast cancer patients treated by NCT. It complements current prognostic models based on tumor characteristics and response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationAllard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 1×
“Any future adjuvant trial based on CTC detection should have to define a threshold compatible with its target population size (five or more CTCs being a rare event), taking into account that one CTC was detected in some healthy individuals with the applied CTC assay (5) and that the low CTC count observed in nonmetast…”
BackgroundBaccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2576 · Cited by 1,047
Self-citationKrebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J.-M., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A., Clack, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7045 · Cited by 868
Bidard, F.-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70069-5 · Cited by 838
Self-citationEstablishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells
Cayrefourcq, L., Mazard, T., Joosse, S., Solassol, J., Ramos, J., Assenat, E., Schumacher, U., Costes, V., Maudelonde, T., Pantel, K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2613 · Cited by 372
Self-citationChallenges in circulating tumor cell detection by the CellSearch system
Andree, K. C., van Dalum, G., & Terstappen, L. W. M. M. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.002 · Cited by 363
Clinical implications of cancer self-seeding
Comen, E., Norton, L., & Massagué, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.64 · Cited by 312
Circulating tumor cells: clinical validity and utility
Cabel, L., Proudhon, C., Gortais, H., Loirat, D., Coussy, F., Pierga, J.-Y., & Bidard, F.-C. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1105-2 · Cited by 219
Self-citationSurgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
King, T. A., & Morrow, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.63 · Cited by 215
Cited by
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Self-citationLiquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Self-citationCirculating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 993
Liquid Biopsy: From Discovery to Clinical Application
Alix-Panabières, C., & Pantel, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1311 · Cited by 953
Self-citation
Metadata
- Authors
- Bidard, F.-C., Michiels, S., Riethdorf, S., Mueller, V., Esserman, L. J., Lucci, A., Naume, B., Horiguchi, J., Gisbert-Criado, R., Sleijfer, S., Toi, M., Garcia-Saenz, J. A., Hartkopf, A., Generali, D., Rothé, F., Smerage, J., Muinelo-Romay, L., Stebbing, J., Viens, P., Magbanua, M. J. M., Hall, C. S., Engebraaten, O., Takata, D., Vidal-Martínez, J., Onstenk, W., Fujisawa, N., Diaz-Rubio, E., Taran, F.-A., Cappelletti, M. R., Ignatiadis, M., Proudhon, C., Wolf, D. M., Bauldry, J. B., Borgen, E., Nagaoka, R., Carañana, V., Kraan, J., Maestro, M., Brucker, S. Y., Weber, K., Reyal, F., Amara, D., Karhade, M. G., Mathiesen, R. R., Tokiniwa, H., Llombart-Cussac, A., Meddis, A., Blanche, P., d'Hollander, K., Cottu, P., Park, J. W., Loibl, S., Latouche, A., Pierga, J.-Y., & Pantel, K.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-12
- Volume
- 110
- Issue
- 6
- Pages
- 560-567
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2796752297
- Cited by
- 277
- References
- 19
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. https://app.cochat.ai/papers/10.1093/jnci/djy018
- The paper
- Bidard, F.-C., Michiels, S., Riethdorf, S., Mueller, V., Esserman, L. J., Lucci, A., Naume, B., Horiguchi, J., Gisbert-Criado, R., Sleijfer, S., Toi, M., Garcia-Saenz, J. A., Hartkopf, A., Generali, D., Rothé, F., Smerage, J., Muinelo-Romay, L., Stebbing, J., Viens, P., . . . Pantel, K. (2018). Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.